Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
PARIS--(BUSINESS WIRE)--May 19, 2025--
Genethon unveiled the 2-year follow-up data from its GNT0004 gene therapy clinical trial for Duchenne Muscular Dystrophy (GNT-016-MDYF) at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13 – 17, 2025. Five patients, aged 6 to 10 years, were treated, 2 at the first dose level and 3 at the second dose level (3x10¹³ vg/kg). The initial part of the clinical trial aimed at selecting the optimal dose (dose escalation phase), evaluating the tolerance and preliminary efficacy of the treatment and determined the effective dose for the pivotal phase of the GNT-016-MDYF trial, which is expected to start in mid-2025 (3x10¹³ vg/kg).
Genethon CEO Frederic Revah observed, 'The results of our gene therapy GNT0004 are very positive in patients treated at the dose of 3x10¹³ vg/kg, both in terms of microdystrophin expression and clinical efficacy criteria. Besides these results, the advantage of our product lies in the selected dose for the pivotal phase, which is lower than those used in other gene therapy trials for Duchenne Muscular Dystrophy. We are currently preparing the pivotal phase that we will conduct in Europe and the US.'
Safety, efficacy, and pharmacodynamic results show good tolerance of GNT0004 associated with transient immunological prophylactic treatment, as well as efficacy data in terms of microdystrophin expression, CPK reduction, and clinical criteria (NSAA, timed tests). Patients treated at the effective dose show prolonged improvement or stabilization of motor functions and significant persistent reduction in creatine kinase (CPK) levels, a key marker of muscle damage.
One-year post-treatment, the comparison of the three patients treated at the effective dose with a group of 34 untreated patients, matched by age and followed in the same centers and by the same practitioners, shows a difference of +4.7 points in the score obtained using the internationally recognized clinical evaluation scale NSAA between treated and untreated patients.
At 24 months post-treatment, key observations include:
About GNT0004 and the trial
The GNT0004 gene therapy is composed of an AAV8 (adeno-associated virus) vector and the optimized hMD1 transgene, a shortened but functional version of the gene encoding dystrophin, the protein deficient in people with DMD. This vector is designed to be expressed in muscle tissue and also in the heart, thanks to a tissue-specific Spc5-12 promoter sequence. GNT0004 is administered by a single intravenous injection. It was developed by Genethon, in partnership with the teams of Prof. Dickson (University of London, Royal Holloway) and the Institut de Myologie (Paris). The trial, sponsored by Genethon, combines Phases 1/2/3, a dose-escalation phase followed by a pivotal phase at the dose finally chosen. The trial is being carried out in France and the UK and includes boys aged 6 to 10 with DMD who have retained their ability to walk.
About Duchenne muscular dystrophy
DMD is a rare, progressive genetic disease affecting all the body's muscles, and mainly boys (1 in 5000). It is due to abnormalities in the gene responsible for producing dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of skeletal and cardiac muscles, loss of walking and respiratory capacity, cardiomyopathy and death between the ages of 20 and 40.
About Genethon
A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a nonprofit organization created by the AFM-Téléthon. The first gene therapy to treat spinal muscular atrophy, incorporating technologies developed at Genethon, is marketed worldwide. With over 240 scientists and professionals, Genethon pursues its goal of developing innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen products from Genethon's R&D or collaborations are in clinical trials for diseases of the liver, blood, immune system, muscles and eyes. A further seven products could enter clinical trials in the next five years. To find out more visit: http://www.genethon.com/.View source version on businesswire.com:https://www.businesswire.com/news/home/20250519497866/en/
CONTACT: Press contact:
Stephanie Bardon
[email protected]
06.45.15.95.87
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE WASHINGTON
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Genethon
Copyright Business Wire 2025.
PUB: 05/19/2025 05:30 AM/DISC: 05/19/2025 05:31 AM
http://www.businesswire.com/news/home/20250519497866/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
British tourist catches Legionnaires' disease in Greece
A British tourist is in hospital after catching a serious lung disease while on an all-inclusive holiday in Greece. Donna Jobling, from west Hull, contracted Legionnaires' disease on the island of Crete and is in intensive care. The 57-year-old, who husband Sid, 69, remains at her bedside, was travelling with easyJet Holidays, which said it had moved other customers out of the hotel where she was staying. "We're so sorry to hear that Ms Jobling is unwell, and we're continuing to support her and her family in every way we can," a spokesperson said. Legionella bug delays £41m health centre opening Ms Jobling has been in an intensive care unit at Venizeleio Hospital in Heraklion since 11 June, her niece Klaire Keita told the BBC. On 5 June she developed a chest infection which triggered acute respiratory failure and pneumonia, her niece added. "We just don't know what's going to happen. We're just trying to do the best we can for her," she said. Fighting back tears, Ms Keita added: "She is just the best person you could ever hope to meet." She said her aunt was "stable but under constant watch". Ms Jobling and her husband were holidaying with another couple, Paula and Nicholas Mason, also from Hull. They returned home on 12 June - the day the couples were meant to fly back together. Ms Mason, 52, said: "I felt awful having to leave my best friend there. "Donna has a heart of gold. She would do anything for anyone. We are all still in shock." Ms Mason said photographs of her friend taken at the start of the break showed her "looking really healthy". "Nicolas and Sid had booked the trip as a surprise for us women. Donna was really looking forward to it." Following Ms Jobling's diagnosis, the Greek health ministry issued a statement to hoteliers in Crete to "raise awareness among all those involved in monitoring the quality of water for human consumption especially with regard to Legionella". The source of the disease has not yet been identified but easyJet Holidays has moved other customers out of the hotel they were staying in, as a precaution. "We've also been in touch with customers who recently returned home from this hotel, to inform them of necessary guidance," a spokesperson said. "Our customers' safety and wellbeing is our top priority, and we'll continue to do all we can to support them." It is understood the hotel affected is currently working with local health authorities on the island. An emergency alert has been issued on the island by the European Centre for Disease Prevention and Control following the diagnosis. Legionnaires' disease is a lung infection most commonly contracted through the inhalation of water droplets containing Legionella bacteria. It is usually caught in places such as hotels, hospitals and office buildings from contaminated air conditioning systems, but can also be contracted from spa pools and hot tubs. Symptoms include shortness of breath, a high temperature and chest pain or discomfort, particularly when breathing or coughing. The disease can induce pneumonia and other respiratory illnesses, which can be life-threatening. Smokers, people over the age of 50 and those who are immunocompromised or have chronic lung conditions are at higher risk of developing the disease. A Foreign, Commonwealth & Development Office spokesperson said: "We are supporting the family of a British woman in hospital in Greece and are in contact with the local authorities." Legionella bug closed mental health ward - report
Yahoo
9 hours ago
- Yahoo
Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say
Working to lose weight in your 40s and 50s may help to reduce your risk of developing a chronic disease, a new study reveals. Researchers based in the U.K. and Finland say they found health benefits in people who lost an average of 6.5 percent of their body weight in early middle age and maintained that weight loss throughout a period of 12 to 35 years. Those benefits especially include a lessened risk for cardiovascular disease and diabetes as well as an overall lower risk of death from chronic disease. 'The benefits of lifestyle-based weight management are widely discussed even though studies have found it surprisingly difficult to demonstrate health benefits beyond the prevention of diabetes,' University of Helsinki professor Dr. Timo Strandberg said in a statement. Strandberg was the lead author of the study which was published recently in the journal JAMA Network Open, the open-access journal of the American Medical Association. To reach these conclusions, the study tracked and analyzed the health of 23,000 white Europeans who were between the ages of 30 and 50 years old using data from three studies, conducted from 1985 to 1988, from 1964 to 1973, and between 2000 and 2013. They sorted the participants into four groups: people with persistent healthy weight, people who were overweight but became a healthy weight, people who were healthy and became overweight, and people who were overweight the entire time. 'Measurement of weight and height was conducted at a time when surgical and pharmacological weight-loss interventions were nearly nonexistent,' the authors noted. The cause of weight loss was not assessed, but given the age of the participants and lack of diagnosed disease, it was more likely intentional than caused by severe chronic conditions or frailty.' In one study, a reduction in body mass from overweight to normal weight over six years in mid-life was tied to a lower risk of developing chronic diseases. There was also a 48 percent lower risk for chronic illness compared to those who remained overweight, which largely held even after excluding participants who developed diabetes during follow-up. Another study showed a 57 percent risk for chronic illness. A third study, with the longest follow-up period, showed that weight loss in mid-life was associated with a 19 percent reduction in overall mortality. 'I'm certain that overall prevention of overweight and obesity starting in early life is absolutely the best thing to do,' Stranberg told The Independent. 'Our study indirectly proves this by showing that persistent healthy weight over the life-course is best.' He said that he hopes the findings will inspire people to see that lifestyle changes can lead to a longer life. 'This is particularly important today as more people are overweight than when the collection of our research data began 35 years ago,' he said in the statement.
